Jonathan C. Meltzer
Known title: EVP, OperationsCIK: 0002103998
Associated companies
Transaction History
| LH | ▼ Sell | Open Market | 839 | $224K | 3/27/2026 | View on chart |
| LH | ▲ Buy | Grant | 2,388 | $0 | 3/26/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 711 | $191K | 3/26/2026 | View on chart |
| LH | ▼ Sell | Open Market | 87 | $25K | 2/12/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 243 | — | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 70 | $20K | 2/11/2026 | View on chart |
| LH | ▼ Sell | Open Market | 91 | $25K | 2/10/2026 | View on chart |
| LH | ▼ Sell | Open Market | 88 | $24K | 2/9/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 82 | $22K | 2/9/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 263 | — | 2/7/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 91 | $25K | 2/6/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 267 | — | 2/6/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.